welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)
study id #: NCT00140894
condition: Adenomatous Polyposis Coli
A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.
Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks
Drug: Comparator: placebo / Duration of Treatment: 24 weeks
start date: March 1, 2003
estimated completion: Not Available
last updated: September 29, 2017
phase of development: Phase 4
size / enrollment: 62
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
- Number and average size of rectal polyps
- Safety and tolerability
- Number and average size of duodenal polyps
- Proportions of patients with improved overall colon rating
- Males or females at least 18 years of age with familial adenomatous polyposis.
expertly curated content related to this topic
Discrepancies in Biopsy Results in Pre- Versus Post-Endoscopic AmpullectomiesAbstract Purpose: Endoscopic ampullec...
Effects of Intervention with Sulindac and Inulin/vsl#3 on Mucosal and Luminal Factors in the Pouch of Patients with ...BACKGROUND/AIM: In order to define futu...
Complementary and Alternative Therapies for CancerMany cancer patients use therapies promo...
Bonnies Diary Dec 07https://jtvcancersupport.com/embed/28653...
Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Developm...Sucampo Pharmaceuticals, Inc., a global ...
8 Myths About Ostomies DebunkedMore than 750,000 Americans live with an...
Inflammatory Bowel Disease and Familial Adenomatous Polyposis Clinical Management and Patients’ Quality of LifeInflammatory bowel disease (IBD) and fam...